Over the last few months on Post-Hoc Live, we’ve done shows about the rapid rise of China’s biotech industry, and how some in the industry are pushing for restrictions to block or slow competition. Tomorrow, we’re going to talk to former FDA commissioner Scott Gottlieb about how the US needs to change if it wants to stay competitive.
Gottlieb (who is now a venture investor and corporate board member) has a recent opinion piece arguing that the US needs to change its approach to clinical trials and regulation, and use its (maybe short-lived) technological advantages if it wants to keep its lead in an industry it spent decades building.
He’ll join us tomorrow at 12:30 p.m. ET. You can watch through our YouTube livestream (click subscribe to get alerts about this and future shows), or click here for a calendar hold.
I’d also recommend checking out our first two China shows with Curie.Bio CEO Zach Weinberg and Jefferies head of Asia healthcare research Cui Cui.
This is going to be a continuing topic on Post-Hoc Live, so please feel free to add questions into the chat when we go live, or send me an email with great ideas for future guests. See you soon!
—Drew
↧